1 true: An acyclic, neutrally charged silanone
at last!
2 Might the "safe aspirin" be here
at last?
3 At last a polynomial retrieval algorithm is introduced.
4 Now,
at last,
a family of auxin efflux carriers has been iden
5 At last,
a molecular classification of HCC based on geno
6 At last,
all the major emitters of greenhouse gases (GHG
7 0.0001; pain at baseline rs = 0.70 and pain
at last assessment rs = 0.76, P < 0.0001).
8 (function at baseline rs = 0.71 and function
at last assessment rs = 0.79, P < 0.0001; pain at baseli
9 The median-follow-up for patients alive
at last assessment was 11.7 months.
10 fter diagnosis of a CE; 26 were asymptomatic
at last assessment, and 18 remained on cardiac medicatio
11 rom 3 to 17 years at onset and 5 to 57 years
at last assessment.
12 lost to follow-up for more than 2 years but
at last available follow-up (3-18 months after surgery)
13 st that such a theoretical understanding may
at last be emerging, and trace its development from hist
14 eterogeneity of this group real progress can
at last be made in determining a precise diagnosis.
15 enosis remains a significant problem but may
at last be yielding to technologic advances.
16 ty in a key group of plants - Brassica - had
at last been characterized.
17 itory action on nerve fiber regeneration has
at last been identified.
18 ng the genetics of T-even bacteriophages has
at last been solved, the answer turning out to involve f
19 e patterns in tough structural composites is
at last beginning to yield to conceptual and computation
20 ial cancer risk declined with increasing age
at last birth (P(trend) < 0.0001).
21 pooled odds ratio per 5-year increase in age
at last birth was 0.87 (95% confidence interval: 0.85, 0
22 In this large pooled analysis, late age
at last birth was independently associated with a reduce
23 rtality, a reverse association with late age
at last birth, and an overall negative association betwe
24 ally infected; mean [standard deviation] age
at last chart review, 20.9 [5.4] years), psychiatric and
25 ber of children, age at first child, and age
at last child) and overall [longevity, body mass index (
26 , rs17293443-C was associated with later age
at last child.
27 At last,
clear evidence has been obtained, from transfor
28 or probable CBD at presentation, 13/19 (68%)
at last clinical assessment.
29 Mean follow-up
at last clinical visit was 66 +/- 46 months.
30 remission (Rem1) and 1- and 3-year remission
at last contact (Rem1/3-LC).
31 sus-host disease, the median Karnofsky score
at last contact date among survivors was 95%.
32 Status
at last contact for survival analysis and mortality at o
33 actors predicting against complete remission
at last contact included onset age>/=10 years (hazard ra
34 atic carriers were right censored at the age
at last contact or age at death.
35 injury cases who were aged 40 years or older
at last contact prior to June 1, 1988, for Alzheimer's d
36 At last contact, 12 were still alive.
37 story of seizures were in terminal remission
at last contact, only 74 (12% of those with a history of
38 taining regimen and surgery and remain alive
at last contact, whereas only one (6%) of 18 patients tr
39 re molecularly positive for the bcr-abl mRNA
at last contact, with a median level of bcr-abl transcri
40 ission; 311 (60%) were in complete remission
at last contact.
41 ntered remission and 13.3% were seizure free
at last contact.
42 ores of 90 or 100, and in 17%, a score of 80
at last contact.
43 At last count almost 30 clinical trials targeting CD19 w
44 At last count, nearly 5000 halogenated natural products
45 re-late life (age of onset <55 years and age
at last diagnosis <55 years), and 36.9% for no PTSD (P <
46 fter adjusting for covariates (VSD site, age
at last dose, sex, and calendar month of the index date)
47 Finally,
at last echocardiographic follow-up, PLG-SAS demonstrate
48 stolic dysfunction or restrictive LV filling
at last evaluation (20% vs. 9%; p = 0.038); 4) 2.4-fold
49 At last evaluation (median, 48 months after vomiting ons
50 ere collected at the time of PoPH diagnosis,
at last evaluation before LT, and within 6 months and be
51 At last evaluation, 20/27 patients (74%) had mPAP <35 mm
52 At last evaluation, 277 patients (91%) are alive at 62+/
53 At last evaluation, SNHL was prevalent in 14% of patient
54 agnosis but showed equivalent renal function
at last evaluation.
55 th 91% experiencing no or only mild symptoms
at last evaluation.
56 of the oldest current age (i.e., age either
at last exam or at death) who lack E4 alleles at the apo
57 roving to 0.18 +/- 0.13 LogMAR (20/40-20/20)
at last examination (p = 0.004), as all the patients gai
58 5.4D) reaching -1.9 +/- 0.9 (-4.0D to -0.6D)
at last examination (p = 0.12).
59 .3D) changing to 1.1 +/- 1.0D (0.0D to 3.0D)
at last examination (p = 0.88).
60 Visual acuity
at last examination was predicted best by visual acuity
61 Visual acuity
at last examination was stable or improved in 33% of pat
62 (age at onset, 89 years) and 2 controls (age
at last examination, 82 and 77 years).
63 At last examination, GBA carriers had worse motor sympto
64 increases in LOD scores were found when age
at last examination/death (LOD score 5.54; P=.000002) or
65 ions reaching 15.9 +/- 3.3 mmHg (10-21 mmHg)
at last follow up (p = 0.21).
66 the end of treatment (T1, P=0.14) and by 18%
at last follow up (T2, P=0.035) compared with treatment
67 At last follow up, ACD and CCD were wider in both groups
68 ; similarly, more patients were disease free
at last follow-up (27% vs 62%, P < 0.0001).
69 vs. 44%; P = 0.010) and long-term cure rate
at last follow-up (8.8 +/- 0.4 years; range, 0.1 to 21.5
70 p = 0.05); they were more likely to meet TFC
at last follow-up (82% vs. 35%, p < 0.001) and have a lo
71 The primary outcome was seizure freedom
at last follow-up (Engel class IA).
72 Modified Rankin score (mRS)
at last follow-up (mean 25.6 months) was dichotomized in
73 At last follow-up (mean, 4.6 years; range, 1-16), 28 (72
74 At last follow-up (mean, 41.8 months; range, 6.5-85.0 mo
75 Seven patients were still responding
at last follow-up (median = 20 months, range 5-67 months
76 Twenty patients required a gait aid (36%)
at last follow-up (median = 60 months, range = 10-172).
77 All others were alive and in remission
at last follow-up (median, 14.7 months).
78 s in this group, but there was no graft loss
at last follow-up (median, 30 [range, 9-84] weeks).
79 apy and were healthy or only mildly disabled
at last follow-up (median, 8 months; range, 6-84 months)
80 ity and there was a 100% graft survival rate
at last follow-up (minimum 4 months).
81 angle of resolution in pseudophakic children
at last follow-up (P < .0001).
82 1.6 logarithm of minimal angle of resolution
at last follow-up (P < .001).
83 After surgery, VA improved to 1.0+/-0.9
at last follow-up (P = 0.002).
84 10.4+/-1.4 cm at baseline and 10.4+/-1.1 cm
at last follow-up (P:=NS).
85 .37 prior to steroid withdrawal to 1.64+0.54
at last follow-up (P=0.027).
86 At last follow-up (range, 0.1 to 12.8 years), five (30.4
87 At last follow-up 10 children have persistent graft dysf
88 r incidence of biopsy-proven acute rejection
at last follow-up 11% (32/151) vs. 21.2% (10/91) among t
89 were cured immediately postoperatively, and
at last follow-up [mean = -9.4 years; range, 0.2-22 year
90 ment efficacy was measured as microbial cure
at last follow-up after treatment.
91 ing the difference between the mean gradient
at last follow-up and the gradient at discharge by the t
92 At last follow-up biopsy, 5 of 9 (56%) patients with a T
93 l/L) were significantly decreased (P < 0.01)
at last follow-up compared with preoperatively.
94 effect was similar or only slightly smaller
at last follow-up compared with the stopping/release tim
95 male, 77% white persons, and the median age
at last follow-up date was 11.5 years.
96 to 0.8 logMAR (0.16 DIN; range 2-0.1 logMAR)
at last follow-up examination (no statistical significan
97 At last follow-up examination, BSCVA had improved in 11
98 All patients were alive
at last follow-up except one.
99 Serum Cr at discharge and
at last follow-up for renal grafts are 4.3+/-0.5 and 1.9
100 atients (14%) with clinical ARVD/C diagnosis
at last follow-up had an abnormal ECG or Holter monitor
101 ll significantly over time and was depressed
at last follow-up in patients receiving more than 300 mg
102 Mortality
at last follow-up in patients with HHV-6 infection (29%,
103 Postoperative success
at last follow-up in the circumferential vs conventional
104 t a median age of 63 months and a median age
at last follow-up of 66 months.
105 the incidence of persistence of the symptom
at last follow-up ranged from 5% to 13%.
106 sis had higher histological activity indices
at last follow-up than patients with stable or reduced f
107 sk Force Criteria (not the "Hamid criteria")
at last follow-up that was absent at enrollment.
108 (P = 0.001), and a lower excess weight loss
at last follow-up visit (P < 0.001) as independent predi
109 ial presentation was 0.36 +/- 0.29logMAR and
at last follow-up visit 0.51 +/- 0.43logMAR.
110 alyzed, and rate of strabismus and nystagmus
at last follow-up visit were calculated.
111 and visual acuity for the pseudophakic eyes
at last follow-up visit.
112 ill autoantibody positive or having diabetes
at last follow-up visit.
113 rcentage of IOP reduction was 23.1 +/- 14.3%
at last follow-up visit.
114 Median age
at last follow-up was 10 years (range, 2-25 years).
115 Death-censored graft survival
at last follow-up was 100% in the ABOi and 98% in 50 com
116 Median visual acuity
at last follow-up was 20/400 (range, 20/30-no light perc
117 as 11.7 years (range, 0.3 to 16.9 years) and
at last follow-up was 27.8 years.
118 Resolution of symptom rate
at last follow-up was 64% in the elderly group versus 86
119 ors, the median Karnofsky performance status
at last follow-up was 85%.
120 Spherical regression
at last follow-up was an average of +0.59 D.
121 ), the proportion of patients with LVEF <55%
at last follow-up was higher in FM versus NFM (29% versu
122 Clinic attendance
at last follow-up was poor (61.9%).
123 Mortality rate and disability
at last follow-up were greater in those who presented wi
124 Mean preoperative cECCs and
at last follow-up were: group 1, 2525+/-338 cells/mm(2)
125 Overall, 9 of 24 patients (37.5%) were alive
at last follow-up with a median follow-up of these survi
126 (ePOST drop >/=2 points from baseline but >1
at last follow-up).
127 At last follow-up, (1/3) of the children with active epi
128 At last follow-up, 1 patient had died, and the remaining
129 .037; median number of glaucoma medications
at last follow-up, 1.49 [IQR 0-2] vs 2.54 [IQR 1-4], P <
130 At last follow-up, 11 of 31 patients progressed and 21 o
131 At last follow-up, 11 patients (17%) had developed recur
132 At last follow-up, 174 (94%) of 185 patients were alive
133 rved their larynx with no sign of recurrence
at last follow-up, 22 (95%) reported normal or near norm
134 At last follow-up, 27 of 30 patients (90%) remain steroi
135 At last follow-up, 28 patients (59.6%) were alive and di
136 At last follow-up, 3 patients died from transplantation-
137 At last follow-up, 34 patients (49%) had significant TR.
138 At last follow-up, 39 (64%) patients were only on beta-b
139 At last follow-up, 4 patients had mild or no symptoms, b
140 At last follow-up, 48% of diabetic and 62% of nondiabeti
141 At last follow-up, 481 (87%) had died, defining a mature
142 At last follow-up, 560 patients were alive with a median
143 At last follow-up, 6 of 19 patients (31.6%) had best-cor
144 At last follow-up, 82.7% of MVR patients had their arrhy
145 At last follow-up, 87% of the surviving patients had no
146 At last follow-up, 92% of the quiescent CNV seemed to co
147 stemic ventricular failure was uncommon, and
at last follow-up, 92% of the Senning group and 89% of t
148 At last follow-up, 99 patients were alive, with a median
149 At last follow-up, a median of 13 months after transplan
150 episodes were recorded after treatment, and
at last follow-up, all 6 surviving patients were free of
151 At last follow-up, all 7 patients with optic neuropathy
152 metastases at surgery, 13 were disease-free
at last follow-up, and none of 2 patients with tumor rec
153 All retinas were attached
at last follow-up, and visual acuity was 20/400 or bette
154 significant differences between groups, and
at last follow-up, both steep and flat keratometry readi
155 ed from 2003 to 2013 and genotyped for PEPT2
At last follow-up, carriers of the PEPT2*1*1 genotype (h
156 At last follow-up, CDVA was 0.09+/-0.10 logMAR in the tP
157 At last follow-up, freedom from AF was 90% (85 of 94), 8
158 ar and systemic findings at presentation and
at last follow-up, investigations, management details, a
159 Compared with baseline,
at last follow-up, left ventricular ejection fraction di
160 m was associated with a slightly higher EDSS
at last follow-up, long-term prognosis in patients with
161 At last follow-up, mean eGFR was 50.2+/-26.1 ml/min per
162 At last follow-up, mean serum creatinine was 1.13+/-0.34
163 At last follow-up, none of the 5 patients presenting wit
164 At last follow-up, patients with recurrent disease had s
165 At last follow-up, PCG showed better median VA than GFCS
166 ) preoperatively to 2831 +/- 236 cells/mm(2)
at last follow-up, representing a mean endothelial cell
167 ported in 65% and 85% of eyes at 1 month and
at last follow-up, respectively.
168 At last follow-up, the circumferential cohort had better
169 At last follow-up, the left ventricular ejection fractio
170 At last follow-up, there was no difference in the overal
171 At last follow-up, there were 46 (18.3%) recurrences; 2
172 At last follow-up, UDVA was 0.27+/-0.25 logMAR in the tP
173 lity was achieved in 72.7% (120/165) of eyes
at last follow-up, while 15.2% (25/165) maintained an im
174 range = 1-5) at onset and 1.74 (range = 0-6)
at last follow-up, with 9% having severe refractory disa
175 At last follow-up, with the use of angiotensin receptor
176 ts having no evidence of progressive disease
at last follow-up.
177 dren recovered without ongoing complications
at last follow-up.
178 treatment; duration of follow-up, and status
at last follow-up.
179 deviations less than 10 prism diopters (PD)
at last follow-up.
180 easures included amount of AHP and deviation
at last follow-up.
181 t least 35 years old (range, 35 to 62 years)
at last follow-up.
182 worse than 20/100 in 75% (9/12) of patients
at last follow-up.
183 val rates after DMEK ranged from 92% to 100%
at last follow-up.
184 Forty-two of 48 TMA leads remain active
at last follow-up.
185 ed pre-ART in 20/29 and in 8/30 participants
at last follow-up.
186 percent were on no antiglaucoma medications
at last follow-up.
187 ad ongoing viremia without clinical symptoms
at last follow-up.
188 nt for remote seizure within prior 6 months)
at last follow-up.
189 ents had recurrence or loss of visual acuity
at last follow-up.
190 ents (14%), but was <5/200 in 34 of 49 (69%)
at last follow-up.
191 week and 1 month after treatment onset, and
at last follow-up.
192 3-week median duration or remission censored
at last follow-up.
193 splant, and 73 were alive without transplant
at last follow-up.
194 filtration rate at 12 months postbiopsy and
at last follow-up.
195 P therapy for a median duration of 34 months
at last follow-up.
196 ith more than 1 year follow-up and 1.4 mg/dL
at last follow-up.
197 myelination and multiple sclerosis diagnosis
at last follow-up.
198 Death-censored graft survival was 100%
at last follow-up.
199 Seventeen patients are still alive
at last follow-up.
200 at the time of withdrawal from the study or
at last follow-up.
201 Seven patients (77.8%) were Engel class I/II
at last follow-up.
202 tation, and 70 were awaiting transplantation
at last follow-up.
203 nety-nine (97%) of the 102 were disease free
at last follow-up.
204 nts potent before treatment, 65% remained so
at last follow-up.
205 removed, 51% were cured immediately, and 41%
at last follow-up.
206 rapy and whole brain radiotherapy were alive
at last follow-up.
207 Each of the 36 patients is PCR negative
at last follow-up.
208 of treatment, and 24% were HCV RNA-negative
at last follow-up.
209 All vascular reconstructions were patent
at last follow-up.
210 hese 14 patients (43%) remained disease-free
at last follow-up.
211 is/fibrosis alone are alive and disease-free
at last follow-up.
212 o had undergone surgery were trichiasis free
at last follow-up.
213 change in 7.7%, and a worsened BCVA in 18.6%
at last follow-up.
214 ellen-equivalent visual acuity (VA), and IOP
at last follow-up.
215 Visual acuity
at last follow-up.
216 rimary end point was symptomatic improvement
at last follow-up.
217 ations to control disease, and had lower IOP
at last follow-up.
218 Seventeen of 21 tumors (81%) were flat
at last follow-up.
219 (41.4%), moderate (18.6%), or severe (6.7%)
at last follow-up.
220 e 85 women included, 62 were free of disease
at last follow-up.
221 (BSCVA) at presentation was 20/46 and 20/48
at last follow-up.
222 a partial response, and 3 had stable disease
at last follow-up.
223 ups at 6 and 12 mo after transplantation and
at last follow-up; however, recipients in group A develo
224 al Project birth cohort (mean age = 37 years
at last follow-up; n = 2,097; 1959-2001).
225 arctions, and less frequently needed therapy
at last followup.
226 employed at baseline, and were age <65 years
at last followup.
227 All vascular reconstructions were patent
at last followup.
228 Serial crystallography
at last generation X-ray synchrotron sources and free el
229 ntervention were more likely to use a condom
at last intercourse, less likely to have a new vaginal s
230 Only first and last name and address
at last-
known residence are required to access the resid
231 essing of graphene and carbon nanotubes have
at last led to the continuous production of high-quality
232 live births, age at first live birth, or age
at last live birth.
233 At last,
network analysis was conducted to identify most
234 At last,
no significant differences were observed betwee
235 At last observation (12-33 weeks), six patients were res
236 nd 50% of Turkish children were malnourished
at last observation (P < 0.005).
237 r reduction in mean +/- SE HAM-A total score
at last-
observation-carried-forward end point compared w
238 By week 1 and
at last-
observation-carried-forward end point, the 3 pre
239 nce bone lead measures and who had completed
at last one Mental Health Index 5-item scale (MHI-5) and
240 Patient ages ranged from 2 to 27 years
at last ophthalmic visit, and follow-up ranged from 0 to
241 Estimated gestational age
at last P. falciparum infection, but not P. vivax infect
242 Clinical status
at last pediatric clinic visit prior to transfer was des
243 At last pediatric follow-up, median age was 17.4 years [
244 At last postoperative follow-up visit, UDVA improved to
245 Best-corrected VAs at first and
at last presentations were 2.2 and 0.0625 logarithm of t
246 At last,
proximity between two conserved amino acids fro
247 efits of genome-wide association studies are
at last realizable.
248 ement of kidney function as assessed by eGFR
at last recorded follow-up compared with eGFR at the tim
249 ween age at first reproduction (AFR) and age
at last reproduction (ALR) in a free-ranging mute swan (
250 in this case series, with a mean (range) age
at last review of 37.1 (16-70) years.
251 ber using augmentative communication methods
at last review).
252 Of the 12 patients (6 males; mean age
at last review, 16 years [range, 2-38 years]), all had h
253 D surgery, and 8.3% had silicone oil in situ
at last review.
254 Mean reported gel use
at last sex act was 89% (95% CI 86-91).
255 acebo) and condom use (64.1% in both groups)
at last sex acts were similar in both groups.
256 Self-reported condom use
at last sex with a male partner increased from 58% in 20
257 ndependent predictor of increased condom use
at last sex with a male partner over time (adjusted odds
258 R] = 0.67; 95% CI, 0.48-0.92) and condom use
at last sexual intercourse (AOR = 0.75; 95% CI, 0.57-0.9
259 Contraceptive method
at last sexual intercourse was assessed by 1 item-respon
260 al and overseas partnerships, and condom use
at last sexual intercourse.
261 item asked whether respondents used a condom
at last sexual intercourse.
262 Median age
at last surgery for the entire population was 60 years (
263 e of 24 months (median intra-patient changes
at last TE examination relative to baseline: -0.2 kPa, p
264 TCD results
at last testing in 108 patients that did not have stroke
265 At last,
the black rice pigment sensitized TiO2 thin fil
266 At last,
the fracture connectivity is determined through
267 At last,
the method is further improved to give a consis
268 At last,
the protein-protein interaction between Dlx3 an
269 At last,
this study also allows an accurate structural d
270 At last,
Ultrasound Doppler velocimeter measured result
271 g-awaited leap to an in vivo biochemistry is
at last underway.
272 er saturations reduced the postmenstrual age
at last use of oxygen therapy (adjusted mean difference,
273 uration of oral contraceptive use, later age
at last use, and more recent use among premenopausal wom
274 0%) maintained their best-ever visual acuity
at last visit (mean follow-up period was 37.8 months).
275 crual (t-test = 2.23, P = 0.028), any damage
at last visit (odds ratio [OR] 23.32, 95% confidence int
276 ved for ECD values (1741+/-274.5 cells/mm(2)
at last visit before rejection vs. 1356+/-380.3 cells/mm
277 f resolution [logMAR]; CCT, 554.1+/-39.1 mum
at last visit before rejection vs. BSCVA, 0.21+/-0.15 lo
278 ion criteria were comparison at baseline and
at last visit of PET and of cardiovascular and cerebral
279 tudy; median (interquartile range [IQR]) age
at last visit was 25 (12-38) months.
280 The mean astigmatism
at last visit was 4.04 +/- 2.21 diopters.
281 BSCVA
at last visit was 7/10 or better in 6 eyes, 4/10 in 1 ey
282 Graft survival rate
at last visit was 90% for Group I and 88% for Group II.
283 Clinical diagnosis
at last visit was MSA for 28 cases.
284 al OFNF (23 male, 27 female, aged 4-48 years
at last visit) and 5 patients with bilateral OFNF (2 mal
285 of Rheumatology damage index (at time 0 and
at last visit) were compared between the 2 groups of wom
286 on), use of TTT, and tumor-foveola distance (
at last visit) were found to be significant risk factors
287 At last visit, 6 of 27 (22%) patients had nystagmus and
288 At last visit, BCVA was better than 20/50 in 131 eyes (5
289 At last visit, Expanded Disability Status Scale was 4.4
290 At last visit, eyes with follow-up showed tumor regressi
291 lensectomy, date of last visit, lens status
at last visit, subsequent retinal surgeries, and retinal
292 dictors (P < 0.05) for losing 1 line or more
at last visit.
293 if performed), and retinal attachment status
at last visit.
294 nal surgeries, and retinal attachment status
at last visit.
295 fined by a modified Rankin Scale score </= 2
at last visit; 84% vs 39%; P < .001) with fewer relapses
296 At last we discuss how the formation of magnetite-based
297 At last,
we apply this method to some real-world network
298 At last,
we briefly outline the allosteric regulation of
299 At last,
we have confirmed that hypothyroid environment
300 At last,
we propose an effective strategy to constrain t